Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genzyme Responds To Cerezyme Impurity Issues At Ireland Facility
According to media reports, Genzyme discovered a chemical called 2,4 dichlorobenzoic acid (2,4 DBCA) in one Cerezyme vial during routine quality control checks at the facility, and has
According to media reports, Genzyme discovered a chemical called 2,4 dichlorobenzoic acid (2,4 DBCA) in one Cerezyme vial during routine quality control checks at the facility, and has
The data were presented at the American College of Cardiology (ACC) meeting in Atlanta, Georgia. The analysis included 1261 patients who were on study medication up to seven
Results from the study showed that the addition of aliskiren did not provide the anticipated effect of limiting adverse changes to the heart’s left ventricle, which is the
Dove has appointed Athena as its exclusive partner for Mainland China and Hong Kong, and is expected to work together to enhance the opportunities for publishing clinical research/basic
Reportedly, both the companies are expected to shortly initiate a technical evaluation of several Microbidex product formulations for their utility against human topical fungal infections. Once the evaluation
The presentation included cell culture performance data comparing multiple stainless steel and SUB production runs at the 1000-liter scale in the company’s cGMP manufacturing facility in Tustin, California.
LLS has committed substantial, multi-year funding to support this collaboration, which is an expansion of partnership between both the companies in July 2009, as part of its Therapy
Primary data from the Navigator (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research) trial, initiated in 2001, were presented at the American College of Cardiology Annual Meeting
Medtronic said the E-Pooled analysis, which included five-year data from the Endeavor I (E-I), Endeavor II (E-II), E-II Continued Access (CA), and Endeavor III (E-III) clinical studies, and
West Coast Clinical Trials said that the new unit is expected to enable it to house additional clinical research participants and expand its base of operations. Tom Pillsworth,